M. Moehler

680 total citations
5 papers, 6 citations indexed

About

M. Moehler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, M. Moehler has authored 5 papers receiving a total of 6 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 2 papers in Oncology and 2 papers in Hepatology. Recurrent topics in M. Moehler's work include Pancreatic and Hepatic Oncology Research (2 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Gastric Cancer Management and Outcomes (2 papers). M. Moehler is often cited by papers focused on Pancreatic and Hepatic Oncology Research (2 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Gastric Cancer Management and Outcomes (2 papers). M. Moehler collaborates with scholars based in Germany, United Kingdom and South Korea. M. Moehler's co-authors include S-E. Al-Batran, María Luisa Limón, F. Rivera Herrero, Annette Stein, Zev A. Wainberg, Oscar K. Serrano, Woo Jin Hyung, Marcia Cruz‐Correa, Gabriel Garbaos and E. Schulze and has published in prestigious journals such as Annals of Oncology, Geburtshilfe und Frauenheilkunde and mediaTUM (Technical University of Munich).

In The Last Decade

M. Moehler

4 papers receiving 6 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Moehler Germany	2	4	3	3	2	1	5	6
Kevin Molina Guatemala	2	4 1.0×	2 0.7×	2 0.7×	2 1.0×		4	9
Mahmut Gümüş Türkiye	3	4 1.0×	3 1.0×	4 1.3×			7	7
Nik Azim Nik Abdullah Malaysia	2	5 1.3×	4 1.3×	3 1.0×			2	8
Jarlath Bolger Ireland	2	4 1.0×	4 1.3×	4 1.3×			3	6
Ingrid Marianne Blomgren Norway	2	4 1.0×	4 1.3×	4 1.3×			2	7
Julia Wolleb Switzerland	3	3 0.8×	4 1.3×	3 1.0×			7	13
A.D. Bueno Cañones Spain	2	3 0.8×	3 1.0×	2 0.7×			3	4
Natalia Gabrovska Bulgaria	2	4 1.0×	4 1.3×	2 0.7×			5	11
Tina Maheswaran United Kingdom	2	5 1.3×	4 1.3×	4 1.3×		1 1.0×	3	11

Countries citing papers authored by M. Moehler

Since Specialization

Citations

This map shows the geographic impact of M. Moehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Moehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Moehler more than expected).

Fields of papers citing papers by M. Moehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Moehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Moehler. The network helps show where M. Moehler may publish in the future.

Co-authorship network of co-authors of M. Moehler

This figure shows the co-authorship network connecting the top 25 collaborators of M. Moehler. A scholar is included among the top collaborators of M. Moehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Moehler. M. Moehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

Al-Batran, S-E., Zev A. Wainberg, Woo Jin Hyung, et al.. (2025). LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma. Annals of Oncology. 36. S1623–S1624.

Al-Batran, S-E., Woo Jin Hyung, M. Moehler, et al.. (2025). LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Annals of Oncology. 36. S150–S151. 1 indexed citations

Moehler, M., Marcia Cruz‐Correa, Ken Kato, et al.. (2025). 392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial. Annals of Oncology. 36. S153–S153. 2 indexed citations

Schmalfeldt, Barbara, Hélène Gilet, Michael Hennig, et al.. (2012). Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Geburtshilfe und Frauenheilkunde. 72(4). 1 indexed citations

Gonschior, A. K., Hélène Gilet, Michael Hennig, et al.. (2011). Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone. mediaTUM (Technical University of Munich). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact